Immune booster vaccine shows promise against deadly brain cancer
NCT ID NCT02649582
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This study tests whether adding a personalized dendritic cell vaccine to standard chemotherapy can help people with newly diagnosed glioblastoma live longer. Twenty patients who had surgery and chemoradiation will receive the vaccine alongside temozolomide. The goal is to see if this combination improves overall and progression-free survival.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
dendritic cell vaccine plus temozolomide chemotherapy
What this could lead to
If it works, this could extend survival for people with newly diagnosed glioblastoma by boosting the immune system to fight the tumor.
What could go wrong
This is an early-phase trial with only 20 participants, so results may not apply to everyone. The vaccine may not work or could cause side effects like inflammation.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Antwerp University Hospital
Edegem, Antwerp, 2650, Belgium